Evolution of the Average Target: GSK plc

Data source: GSK plc(GSK)
Evolution of the Average Target - GSK plc

Evolution of the Target Price: GSK plc

Data source: GSK plc(GSK)
Evolution of the Target Price - GSK plc

Changes in Analyst Recommendations: GSK plc

Data source: GSK plc(GSK)
efd192ec95dceb62171009471ebf6121.nwGhYKBzCs_NHThjxHzAZhURsLnIh3EsDq6bVZGwWRg.zVDKLJcQWo6eZFUksDH1KmZn8-mM3kFIeuzMCuj0HyHWYuJW8xJBoK4sDA~353c6b28967ec62a33300c31005d5c2f
26/10 GSK plc : JP Morgan reaffirms its Sell rating ZD
21/10 GSK plc : JP Morgan keeps a Sell rating ZD
19/10 GSK plc : Jefferies reiterates its Buy rating ZD
15/10 GSK plc : UBS remains Neutral ZD
14/10 Berenberg still a buyer of GSK, considering stock undervalued Zonebourse
14/10 GSK plc : Berenberg remains its Buy rating ZD
14/10 GSK's Pharma Business to Drive Future Returns Amid Oncology Boost, Berenberg Says MT
14/10 RBC Expects 'In-line' Q3 Results for GSK as Strong HIV, Asthma Drug Sales Offset Vaccine Softness MT
13/10 GSK Likely to Deliver In-Line Q3, RBC Says MT
13/10 GSK plc : RBC gives a Neutral rating ZD
08/10 GSK plc : Gets a Sell rating from JP Morgan ZD
07/10 GSK plc : Berenberg remains its Buy rating ZD
01/10 GSK plc : JP Morgan reiterates its Sell rating ZD
29/09 GSK plc : Gets a Neutral rating from Deutsche Bank ZD
29/09 GSK plc : Jefferies keeps its Buy rating ZD
18/09 GSK plc : Deutsche Bank remains Neutral ZD
17/09 GSK plc : UBS is Neutral ZD
16/09 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
15/09 GSK plc: Priced for the storm, being built for thereafter Alphavalue
15/09 GSK Upgraded to Buy as Berenberg Notes Pipeline Momentum; Price Target Raised MT
15/09 Berenberg Upgrades GSK to Buy, Raises PT MT
15/09 Berenberg Upgrades GSK to Buy From Hold, Raises Price Target to $60 From $54 MT
15/09 Berenberg likes GSK; Deutsche Bank lifts Astra AN
15/09 GSK plc : Deutsche Bank remains Neutral ZD
15/09 GSK plc : Berenberg gives a Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.27%
+4.92%
-0.68%
-2.56%
+13.62%
-2.85%
+22.47%
-10.64%
+0.95%
Average +3.28%
Weighted average by Cap. +3.54%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
19.15GBP
Average target price
21.75GBP
Spread / Average Target
+13.57%
High Price Target
30.10GBP
Spread / Highest target
+57.18%
Low Price Target
14.55GBP
Spread / Lowest Target
-24.02%

Analyst Consensus Detail

Analyst consensus - GSK plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - GSK plc
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - GSK plc